NCT05398237View on ClinicalTrials.gov

An Assessment of TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light

NACompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2023

Conditions
Sun Damaged Skin
Interventions
OTHER

Solar Simulated Light (SSL)

Acute SSL will be delivered to sun damaged skin at a rate of two-times the minimal erythema dose of each individual subject. Minimal erythema dose is defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 22-26 hours post-exposure.

Trial Locations (1)

85724

University of Arizona, Tucson

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER

NCT05398237 - An Assessment of TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light | Biotech Hunter | Biotech Hunter